Retinal Vein Occlusion - Pipeline Review, H1 2018
Retinal Vein Occlusion - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2018, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 3, 11, 1 and 1 respectively.
Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Acucela Inc
Addmedica SAS
Annexin Pharmaceuticals AB
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
EyeGate Pharmaceuticals Inc
Eyevensys SAS
Formycon AG
Gene Signal International SA
Graybug Vision Inc
Lupin Ltd
Mabion SA
Novartis AG
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Profarma
Regeneron Pharmaceuticals Inc
SciFluor Life Sciences LLC
ThromboGenics NV
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinal Vein Occlusion - Overview
Retinal Vein Occlusion - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinal Vein Occlusion - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinal Vein Occlusion - Companies Involved in Therapeutics Development
Acucela Inc
Addmedica SAS
Annexin Pharmaceuticals AB
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
EyeGate Pharmaceuticals Inc
Eyevensys SAS
Formycon AG
Gene Signal International SA
Graybug Vision Inc
Lupin Ltd
Mabion SA
Novartis AG
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Profarma
Regeneron Pharmaceuticals Inc
SciFluor Life Sciences LLC
ThromboGenics NV
Retinal Vein Occlusion - Drug Profiles
ACU-6151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aganirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-9778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LKA-651 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ocriplasmin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTX-TKI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit VEGF for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squalamine lactate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triamcinolone acetonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinal Vein Occlusion - Dormant Projects
Retinal Vein Occlusion - Discontinued Products
Retinal Vein Occlusion - Product Development Milestones
Featured News & Press Releases
May 09, 2018: Clearside Biomedical Provides Update on Pivotal Phase 3 Trial Results of Suprachoroidal CLS-TA
Mar 06, 2018: Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion
Jun 08, 2017: Clearside Biomedical’s TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting
Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development for Retinal Vein Occlusion, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Retinal Vein Occlusion - Pipeline by Acucela Inc, H1 2018
Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2018
Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H1 2018
Retinal Vein Occlusion - Pipeline by Celon Pharma SA, H1 2018
Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2018
Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H1 2018
Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals Inc, H1 2018
Retinal Vein Occlusion - Pipeline by Eyevensys SAS, H1 2018
Retinal Vein Occlusion - Pipeline by Formycon AG, H1 2018
Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H1 2018
Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H1 2018
Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2018
Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2018
Retinal Vein Occlusion - Pipeline by Novartis AG, H1 2018
Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2018
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H1 2018
Retinal Vein Occlusion - Pipeline by Profarma, H1 2018
Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Retinal Vein Occlusion - Pipeline by SciFluor Life Sciences LLC, H1 2018
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2018
Retinal Vein Occlusion - Dormant Projects, H1 2018
Retinal Vein Occlusion - Discontinued Products, H1 2018List of Figures
Number of Products under Development for Retinal Vein Occlusion, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Research Methodology
The research study released with title "Retinal Vein Occlusion - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Retinal Vein Occlusion Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Retinal Vein Occlusion Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Retinal Vein Occlusion Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Retinal Vein Occlusion Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Retinal Vein Occlusion - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
